Advertisement
New Zealand markets closed

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NZD/USD

    0.5945
    +0.0008 (+0.13%)
     

  • NZD/EUR

    0.5550
    +0.0004 (+0.07%)
     

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • OIL

    82.72
    -0.09 (-0.11%)
     

  • GOLD

    2,331.50
    -6.90 (-0.30%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    18,088.70
    -48.95 (-0.27%)
     

  • Hang Seng

    17,259.62
    +58.35 (+0.34%)
     

  • NIKKEI 225

    37,764.45
    -695.63 (-1.81%)
     

  • NZD/JPY

    92.3450
    +0.2300 (+0.25%)
     

Is Moderna Stock a Buy Now After the U.K.'s Omicron Vaccine Approval?

Dan Caplinger, The Motley Fool
·3-min read

Shares of COVID-19 vaccine pioneer Moderna (NASDAQ: MRNA) moved higher on Monday morning, rising more than 3% as the company announced more good news with its virus-fighting efforts. Specifically, Moderna said that it has received approval for use in the U.K. for what the company is calling its "next-generation COVID-19 vaccine." The body oversees immunization approvals in the U.K., and this is the first time that it or any other regulatory agency has approved a bivalent vaccine designed to address the omicron variant.

Continue reading